Investigation of the management and risk of febrile neutropenia associated with chemotherapy in the urological field: A multicenter, retrospective analysis

Koichiro Wada, Ryuta Tanimoto, Hiroyuki Nose, Shinya Uehara, Toyohiko Watanabe, Hiroshi Hayami, Shingo Nagai, Mitsuru Yasuda, Takashi Deguchi, Keisuke Shigeta, Satoshi Yazawa, Eiji Kikuchi, Mototsugu Oya, Jiro Hashimoto, Teruhisa Uehara, Yuichiro Kurimura, Yoshiki Hiyama, Satoshi Takahashi, Taiji Tsukamoto, Takehiko ShoRyoichi Hamasuna, Jun Miyazaki, Yoshikazu Togo, Rikiya Taoka, Atsushi Nakao, Shingo Yamamoto, Kanao Kobayashi, Akio Matsubara, Kiyohito Ishikawa, Hiromi Kumon, Tetsuro Matsumoto

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In Japan, chemotherapy for urogenital malignant diseases is commonly performed by urologists and febrile neutropenia (FN) is one of the major adverse events associated with chemotherapy, however, few reports exist from the urological field about FN. In this present study, a total of 883 courses of chemotherapy (326 patients) performed from 2010 to 2011 at 10 University Hospitals were retrospectively reviewed. The regimens were GC (gemcitabine and cisplatin), GCP (gemcitabine, cisplatin and paclitaxel) and M-VAC (methotrexate, vinblastine, doxorubicin, cisplatin) for urothelial carcinoma, and EP (etoposide and cisplatin) and BEP (bleomycin, etoposide and cisplatin) for testicular cancer. In 81 courses (9.2%, 66 patients; 20.2%) including FN, antimicrobials and granulocyte-colony stimulating factor (G-CSF) were administered in 69 courses (85.2%) and in 77 courses (95.1%), respectively. The MASCC risk-index score was evaluated in no more than 51 courses (63.0%) and 1 patient with 18 points on the MASCC score died due to myelotoxicity and infections. According to statistical investigations, FN is significantly more frequent in GCP and M-VAC than in GC (p = 0.0073, <0.0001) and in a similar manner in BEP than in EP (p = 0.0405). In patients with afebrile neutropenia (AN), observed in 232 courses (26.3%), antimicrobials and G-CSF were administered in 5 courses (2.2%) and in 144 courses (62.1%), respectively. Further evidence from the urological field is required to investigate the treatment and risk of FN for management of patients with urogenital malignancies.

Original languageEnglish
Pages (from-to)374-381
Number of pages8
JournalJapanese Journal of Chemotherapy
Volume62
Issue number3
Publication statusPublished - May 2014

    Fingerprint

Keywords

  • Anticancer chemotherapy
  • Febrile neutropenia
  • Multicenter trial
  • Urology

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Wada, K., Tanimoto, R., Nose, H., Uehara, S., Watanabe, T., Hayami, H., Nagai, S., Yasuda, M., Deguchi, T., Shigeta, K., Yazawa, S., Kikuchi, E., Oya, M., Hashimoto, J., Uehara, T., Kurimura, Y., Hiyama, Y., Takahashi, S., Tsukamoto, T., ... Matsumoto, T. (2014). Investigation of the management and risk of febrile neutropenia associated with chemotherapy in the urological field: A multicenter, retrospective analysis. Japanese Journal of Chemotherapy, 62(3), 374-381.